研究报告 |
|
|
|
|
工程化外泌体介导巨噬细胞清除肿瘤外泌体* |
王璐1,陈梦丽1,何芳1,2,项建1,尹斌成1,2,3,**(),叶邦策1,2 |
1.华东理工大学生物反应器国家重点实验室 上海 200237 2.浙江工业大学药学院 长三角绿色制药协同创新中心 杭州 310032 3.石河子大学化学化工学院 石河子 832003 |
|
Clearance of Tumor Exosomes by Engineered Exosomes-assisted Phagocytosis of Macrophages |
WANG Lu1,CHEN Meng-li1,HE Fang1,2,XIANG Jian1,YIN Bin-cheng1,2,3,**(),YE Bang-ce1,2 |
1. State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China 2. Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310032, China 3. School of Chemistry and Chemical Engineering, Shihezi University, Shihezi 832003 China |
引用本文:
王璐,陈梦丽,何芳,项建,尹斌成,叶邦策. 工程化外泌体介导巨噬细胞清除肿瘤外泌体*[J]. 中国生物工程杂志, 2022, 42(6): 1-11.
WANG Lu,CHEN Meng-li,HE Fang,XIANG Jian,YIN Bin-cheng,YE Bang-ce. Clearance of Tumor Exosomes by Engineered Exosomes-assisted Phagocytosis of Macrophages. China Biotechnology, 2022, 42(6): 1-11.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2201020
或
https://manu60.magtech.com.cn/biotech/CN/Y2022/V42/I6/1
|
[1] |
Xu Z J, Zeng S S, Gong Z C, et al. Exosome-based immunotherapy: a promising approach for cancer treatment. Molecular Cancer, 2020, 19(1): 160.
doi: 10.1186/s12943-020-01278-3
|
[2] |
Marleau A M, Chen C S, Joyce J A, et al. Exosome removal as a therapeutic adjuvant in cancer. Journal of Translational Medicine, 2012, 10: 134.
doi: 10.1186/1479-5876-10-134
|
[3] |
Yokoi A, Ochiya T. Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology. Seminars in Cancer Biology, 2021, 74: 79-91.
doi: 10.1016/j.semcancer.2021.03.032
|
[4] |
Guo Y X, Ji X, Liu J B, et al. Effects of exosomes on pre-metastatic niche formation in tumors. Molecular Cancer, 2019, 18(1): 39.
doi: 10.1186/s12943-019-0995-1
|
[5] |
Morad G, Carman C V, Hagedorn E J, et al. Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano, 2019, 13(12): 13853-13865.
doi: 10.1021/acsnano.9b04397
|
[6] |
Obenauf A C, Massagué J. Surviving at a distance: organ-specific metastasis. Trends in Cancer, 2015, 1(1): 76-91.
doi: S2405-8033(15)00010-2
pmid: 28741564
|
[7] |
Steinbichler T B, Dudás J, Riechelmann H, et al. The role of exosomes in cancer metastasis. Seminars in Cancer Biology, 2017, 44: 170-181.
doi: S1044-579X(17)30024-X
pmid: 28215970
|
[8] |
Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. Journal of Molecular Medicine (Berlin, Germany), 2013, 91(4): 431-437.
doi: 10.1007/s00109-013-1020-6
|
[9] |
Nishida-Aoki N, Tominaga N, Takeshita F, et al. Disruption of circulating extracellular vesicles as a novel therapeutic strategy against cancer metastasis. Molecular Therapy, 2017, 25(1): 181-191.
doi: S1525-0016(16)45363-3
pmid: 28129113
|
[10] |
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology, 2020, 17(8): 807-821.
|
[11] |
Ye H, Wang K Y, Lu Q, et al. Nanosponges of circulating tumor-derived exosomes for breast cancer metastasis inhibition. Biomaterials, 2020, 242: 119932.
doi: 10.1016/j.biomaterials.2020.119932
|
[12] |
Xie X, Nie H, Zhou Y, et al. Eliminating blood oncogenic exosomes into the small intestine with aptamer-functionalized nanoparticles. Nature Communications, 2019, 10(1): 5476.
doi: 10.1038/s41467-019-13316-w
|
[13] |
Yin W M, Li Y W, Gu Y Q, et al. Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacologica Sinica, 2020, 41(7): 902-910.
doi: 10.1038/s41401-020-0417-3
|
[14] |
Cheng L L, Zhang X G, Tang J J, et al. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD 47 signal for combined photothermal therapy and cancer immunotherapy. Biomaterials, 2021, 275: 120964.
doi: 10.1016/j.biomaterials.2021.120964
|
[15] |
Fu Z Y, Xiang J. Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. International Journal of Molecular Sciences, 2020, 21(23): 9123.
doi: 10.3390/ijms21239123
|
[16] |
Burgos-Ravanal R, Campos A, Díaz-Vesga M C, et al. Extracellular vesicles as mediators of cancer disease and as nanosystems in theranostic applications. Cancers, 2021, 13(13): 3324.
doi: 10.3390/cancers13133324
|
[17] |
Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity, 2012, 36(5): 705-716.
doi: 10.1016/j.immuni.2012.05.008
pmid: 22633458
|
[18] |
Wang D L, Song Y L, Zhu Z, et al. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochemical and Biophysical Research Communications, 2014, 453(4): 681-685.
doi: 10.1016/j.bbrc.2014.09.023
|
[19] |
Jia D L, Yang Y J, Yuan F J, et al. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. International Journal of Pharmaceutics, 2020, 586: 119541.
doi: 10.1016/j.ijpharm.2020.119541
|
[20] |
Delcanale P, Porciani D, Pujals S, et al. Aptamers with tunable affinity enable single-molecule tracking and localization of membrane receptors on living cancer cells. Angewandte Chemie International Edition, 2020, 59(42): 18546-18555.
|
[21] |
Xu M, Feng T, Liu B W, et al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics, 2021, 11(18): 8926-8944.
doi: 10.7150/thno.62330
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|